NSE - Delayed Quote INR

Cipla Limited (CIPLA.NS)

1,406.20

+8.00

(+0.57%)

At close: April 25 at 3:30 PM GMT+5:30

India pharma companies develop versions of Wegovy to get in on weight-loss windfall

Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.

Reuters 2 months ago

NVO

CIPLA.NS
+0.57%
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products

Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products

PR Newswire 3 months ago

CPLFY
India shares close at two-week low as hawkish Fed spooks investors

India's benchmark indexes on Thursday closed at a two-week low in a broad-based selloff, after the U.S. Federal Reserve signalled that interest rates will remain elevated for longer. The Nifty 50 closed 0.8% lower at 19,742.35 points, its lowest close since Sept.7, while the S&P BSE Sensex declined about 0.85% to 66,230.24 points. The Fed on Wednesday held key interest rates unchanged as widely expected, but warned that the battle against inflation was far from over.

Reuters 7 months ago

CIPLA.NS
+0.57%
ADANIGREEN.NS
India's Torrent Pharma says nothing to disclose on Cipla stake buy report

India's Torrent Pharmaceuticals on Friday said it has no information requiring disclosure under listing regulations, after the Economic Times reported that it was in talks to buyout the stake of rival Cipla's top shareholders. Torrent said it "did not comment on speculative reports in the absence of verified data," and that it was not in a position to comment on the movement in its share price. Torrent Pharma is interested in buying out top shareholder Hamied family's 33.47% stake in Cipla and is trying to put together financing for the purchase, ET reported.

Reuters 7 months ago

CIPLA.NS
+0.57%
TORNTPHARM.BO
Blackstone to submit bid for stake in India's Cipla- report

The stake sale will formally start the exit of the Hamied family who had founded Cipla in 1935, the report added. Cipla and Blackstone did not immediately respond to Reuters' request for comment. The move will also trigger an open offer for an additional 26% of Cipla, upon full subscription of which Blackstone would end up owning as much as 59.4% of Cipla's stake, according to the report.

Reuters 8 months ago

CIPLA.NS
+0.57%
BX
Top shareholders of India's Cipla looking to sell stake - report

Top shareholders of Indian drugmaker Cipla are in talks to sell a part of their stake in the company to private equity players including Blackstone and Baring Asia, Moneycontrol reported on Thursday. The company is not aware of any event that requires disclosure under listing regulations, Cipla said in a exchange statement. The drugmaker's shareholders are looking to sell a part of their total 33.47% stake in the firm to strategic investors who can oversee a revamp, help enhance capital allocation and improve operational efficiency, the report said, citing sources familiar with the matter.

Reuters 8 months ago

CIPLA.NS
+0.57%
UPDATE 1-US unit of India's Cipla recalls six batches of bronchospasm inhaler

Indian drugmaker Cipla said on Friday its U.S. unit was recalling six batches of albuterol sulfate inhalation aerosol due to a "container defect". "The company is initiating a recall in the U.S. due to a market complaint for one single inhaler, where leakage was observed through the inhaler valve," the pharmaceutical company said in a statement. The company's "Albuterol Sulfate HFA Inhalation Aerosol" is a generic therapeutic equivalent version of an inhaler from Merck & Co, according to Cipla's website.

Reuters 9 months ago

CIPLA.NS
+0.57%
Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla"), today announced that its wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level.

PR Newswire 9 months ago

CPLFY
INDIA STOCKS-Indian shares rise on earnings boost, inflation optimism

Twelve of the 13 major sectoral indexes advanced, with auto and realty stocks rising 0.7% and 4.32%, respectively. Tata Motors gained 2.89%, powering the rise in the auto index, after posting record revenue and setting its first dividend in 7 years. DLF rose 7.39% to a 52-week high and boost realty stocks after reporting a surge in fourth-quarter profit.

Reuters 11 months ago

TATAMOTORS.BO

CIPLA.NS
+0.57%
India's Cipla posts 45% jump in Q4 profit on domestic drugs business boost

Cipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business. Shares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses. Cipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3.62 billion rupees a year earlier.

Reuters 11 months ago

CIPLA.NS
+0.57%

Performance Overview

Return	CIPLA.NS	S&P BSE SENSEX
YTD	+12.83%	+2.91%
1-Year	+56.99%	+23.78%
3-Year	+53.09%	+55.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cipla Limited (CIPLA.NS)

India pharma companies develop versions of Wegovy to get in on weight-loss windfall

Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products

India shares close at two-week low as hawkish Fed spooks investors

India's Torrent Pharma says nothing to disclose on Cipla stake buy report

Blackstone to submit bid for stake in India's Cipla- report

Top shareholders of India's Cipla looking to sell stake - report

UPDATE 1-US unit of India's Cipla recalls six batches of bronchospasm inhaler

Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect

INDIA STOCKS-Indian shares rise on earnings boost, inflation optimism

India's Cipla posts 45% jump in Q4 profit on domestic drugs business boost

Performance Overview